Positive Results From The Phase Ib Clinical Study of NeuroRestore ACD856, Under Development for Alzheimer's

STOCKHOLM, SE / ACCESS Newswire / June 16, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced …